<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang Y</submitter><funding>Guangzhou Science and Technology Project</funding><funding>Guangdong Provincial Applied Science and Technology Research &amp;amp; Development Program</funding><funding>National Natural Science Foundation of China</funding><pagination>12</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6570921</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7</volume><pubmed_abstract>We previously identified a &lt;i>TCR Vβ&lt;/i>21 T cell clone which was specific to CML patients, and demonstrated that &lt;i>TCR Vα&lt;/i>13/&lt;i>β&lt;/i>21 gene-modified CD3&lt;sup>+&lt;/sup> T cells had specific cytotoxicity for HLA-A11&lt;sup>+&lt;/sup> K562 cells. However, it remains unclear which antigen is specifically recognized by the &lt;i>TCR Vβ&lt;/i>21 T cell clone. In this study, CD3&lt;sup>+&lt;/sup> T cells from healthy donor peripheral blood were stimulated with the WT1 peptide or mixed BCR-ABL peptides in the presence or absence of IL-2 and IL-7. The distribution of the &lt;i>TCR Vβ&lt;/i> repertoire was analyzed after different stimulations. We found that the mixed BCR-ABL peptides induced clonally expanded &lt;i>Vβ&lt;/i>7-9-&lt;i>Dβ&lt;/i>2-&lt;i>Jβ&lt;/i>2-7 T cells while the Wilms Tumor 1 peptide induced clonally expanded &lt;i>Vβ&lt;/i</pubmed_abstract><journal>Biomarker research</journal><pubmed_title>Identification of &lt;i>TCR Vβ&lt;/i>11-2-&lt;i>Dβ&lt;/i>1-&lt;i>Jβ&lt;/i>1-1 T cell clone specific for WT1 peptides using high-throughput &lt;i>TCRβ&lt;/i> gene sequencing.</pubmed_title><pmcid>PMC6570921</pmcid><funding_grant_id>20180710004</funding_grant_id><funding_grant_id>201510010211</funding_grant_id><funding_grant_id>2016B020237006</funding_grant_id><funding_grant_id>91642111</funding_grant_id><funding_grant_id>81770152</funding_grant_id><funding_grant_id>201803040017</funding_grant_id><pubmed_authors>Xu L</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Wei W</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Zha X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification of &lt;i>TCR Vβ&lt;/i>11-2-&lt;i>Dβ&lt;/i>1-&lt;i>Jβ&lt;/i>1-1 T cell clone specific for WT1 peptides using high-throughput &lt;i>TCRβ&lt;/i> gene sequencing.</name><description>We previously identified a &lt;i>TCR Vβ&lt;/i>21 T cell clone which was specific to CML patients, and demonstrated that &lt;i>TCR Vα&lt;/i>13/&lt;i>β&lt;/i>21 gene-modified CD3&lt;sup>+&lt;/sup> T cells had specific cytotoxicity for HLA-A11&lt;sup>+&lt;/sup> K562 cells. However, it remains unclear which antigen is specifically recognized by the &lt;i>TCR Vβ&lt;/i>21 T cell clone. In this study, CD3&lt;sup>+&lt;/sup> T cells from healthy donor peripheral blood were stimulated with the WT1 peptide or mixed BCR-ABL peptides in the presence or absence of IL-2 and IL-7. The distribution of the &lt;i>TCR Vβ&lt;/i> repertoire was analyzed after different stimulations. We found that the mixed BCR-ABL peptides induced clonally expanded &lt;i>Vβ&lt;/i>7-9-&lt;i>Dβ&lt;/i>2-&lt;i>Jβ&lt;/i>2-7 T cells while the Wilms Tumor 1 peptide induced clonally expanded &lt;i>Vβ&lt;/i</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019</publication><modification>2025-04-26T02:07:37.41Z</modification><creation>2019-07-24T07:18:57Z</creation></dates><accession>S-EPMC6570921</accession><cross_references><pubmed>31223481</pubmed><doi>10.1186/s40364-019-0163-1</doi></cross_references></HashMap>